论文部分内容阅读
目的:通过使用频域相干光学断层深度增强成像测量正常个体脉络膜厚度(CT)以评估眼部使用0.15%酒石酸溴莫尼定对眼后节的潜在影响。方法:前瞻性、安慰剂对照干预性临床试验,包括32例32眼正常个体。第1d,受试者接受一滴无防腐剂人工泪液作为安慰剂;第2d,接受一滴0.15%酒石酸溴莫尼定。收集每次用药前及用药后1、3和5h,眼压,眼灌注压(OPP)以及EDI-SD-OCT数据。结果:相较于最初测量结果,局部应用0.15%酒石酸溴莫尼定后,在下凹(P=0.001),颞凹1500μm处(P=0.003),鼻凹1500μm处(P=0.003)测得脉络膜厚度显著增加。整个研究过程中,安慰剂组脉络膜厚度未发生变化(P>0.05)。分别使用安慰剂和溴莫尼定后眼灌注压没有显著降低(P>0.05)。研究中未观察到不良反应。结论:与预期相悖,局部应用0.15%酒石酸溴莫尼定导致下凹、颞凹、鼻凹处脉络膜厚度增加。这一结论可能与脉络膜血管自动调节机制有关
OBJECTIVE: To assess the ocular potential impact of ocular use of 0.15% brimonidine tartrate on posterior segments of the eye by measuring the choroidal thickness (CT) of normal individuals using frequency-domain coherence tomography depth enhanced imaging. METHODS: A prospective, placebo-controlled, intervened clinical trial comprised 32 subjects with 32 eyes as normal. On Day 1, subjects received one drop of preservative-free artificial tears as a placebo; on Day 2, one drop of 0.15% brimonidine tartrate was received. Intraocular pressure, ocular perfusion pressure (OPP), and EDI-SD-OCT data were collected before and after 1, 3 and 5 h of administration. RESULTS: Compared with the initial measurement, the choroid was measured in the concave (P = 0.001), the temporal concave 1500 μm (P = 0.003) and the nasal concave 1500 μm (P = 0.003) after topical application of brimonidine tartrate 0.15% Thickness increases significantly. There was no change in choroidal thickness in the placebo group throughout the study (P> 0.05). There was no significant decrease in ocular perfusion pressure between placebo and brimonidine (P> 0.05). No adverse reactions were observed in the study. CONCLUSIONS: Contrary to expectations, topical application of brimonidine tartrate 0.15% resulted in an increase in the thickness of the choroid in the concave, temporal and nasal cavities. This conclusion may be related to choroidal vascular autoregulation mechanism